Skip to main content

Table 1 General information for the non-diabetic individual A and the four diabetic patients B–E

From: Personalizing the safe, appropriate and effective concentration(s) of ozone for a non-diabetic individual and four type II diabetic patients in autohemotherapy through blood hemoglobin analysis

Samples

Age

Gender

Hb concentration (mg/ml) based on absorbance reading at 280 nm post ozonation and dialysis

TAC (mM)

Duration of disease (medication taken)

Individual A

46

Male

Non-O3: 100.70

15 μg/ml O3: 136.48

35 μg/ml O3: 110.01

55 μg/ml O3: 111.48

0.274 ± 0.009

–

Patient B

56

Female

Non-O3: 86.63

15 μg/ml O3: 79.61

35 μg/ml O3: 103.14

55 μg/ml O3: 75.38

0.207 ± 0.006

18 years

(Metformin)

Patient C

66

Male

Non-O3: 66.12

15 μg/ml O3: 94.41

35 μg/ml O3: 80.59

55 μg/ml O3: 70.15

0.341 ± 0.015

20 years

(Insulin)

Patient D

60

Male

Non-O3: 48.41

15 μg/ml O3: 63.92

35 μg/ml O3: 74.52

55 μg/ml O3: 86.88

0.370 ± 0.013

1 year

(Metformin)

Patient E

41

Female

Non-O3: 62.80

15 μg/ml O3: 59.38

35 μg/ml O3: 57.40

55 μg/ml O3: 55.65

0.271 ± 0.029

5 years

(Insulin)